CMV-dCasRx-ccdB
(Plasmid
#221003)
-
Purpose(Empty Backbone) Destination vector for Gateway cloning of ORFs into the C-terminus of dCasRx. CMV promoter. Transient expression.
-
Depositing Labs
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 221003 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepAC1801_pmax-dCasRx (Addgene #118634)
-
Vector typeMammalian Expression, CRISPR
Growth in Bacteria
-
Bacterial Resistance(s)Chloramphenicol and Ampicillin, 25 & 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)ccdB Survival
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameNone
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
This was the destination vector used for generating the dCasRx-SF library for screening by co-transfection with the luciferase reporters. We have found that cloning dCasRx-SFs into the pXR002 backbone gave greater transfection efficiency for endogenous applications. We recommend using the EF1a-dCasRx-RBM25 vector (Addgene #221001) for endogenous targeting.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
CMV-dCasRx-ccdB was a gift from Benjamin Blencowe & Mikko Taipale (Addgene plasmid # 221003 ; http://n2t.net/addgene:221003 ; RRID:Addgene_221003) -
For your References section:
Efficient, specific, and combinatorial control of endogenous exon splicing with dCasRx-RBM25. Li JD, Taipale M, Blencowe BJ. Mol Cell. 2024 Jul 11;84(13):2573-2589.e5. doi: 10.1016/j.molcel.2024.05.028. Epub 2024 Jun 24. 10.1016/j.molcel.2024.05.028 PubMed 38917795